A novel role for the anti-senescence factor TBX2 in DNA repair and cisplatin resistance

Cell Death and Disease

Volumn 4, Issue 10, 2013, Pages

  Wansleben, S ^a   Davis, E ^a   Peres, J ^a   Prince, S ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Breast cancer; Cisplatin resistance; Mitotic catastrophe; P53; TBX2

Indexed keywords

ATM PROTEIN; CHECKPOINT KINASE 2; CISPLATIN; CYCLIN B1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; HISTONE H2AX; PROTEIN P53; TRANSCRIPTION FACTOR T BET;

APOPTOSIS; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CELL AGING; CELL DEATH; CELL FATE; CELL SURVIVAL; CELL TRANSFORMATION; CELL VIABILITY; DNA DAMAGE; DNA REPAIR; DRUG EFFICACY; G2 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; MELANOMA CELL; MITOSIS; POLYPLOIDY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; S PHASE CELL CYCLE CHECKPOINT; SENESCENCE; SIGNAL TRANSDUCTION;

ATAXIA TELANGIECTASIA MUTATED PROTEINS; CELL AGING; CELL LINE, TUMOR; CHECKPOINT KINASE 2; CISPLATIN; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HUMANS; MODELS, BIOLOGICAL; PROTEIN STABILITY; RNA, SMALL INTERFERING; S PHASE; SIGNAL TRANSDUCTION; T-BOX DOMAIN PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84887461962     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.365     Document Type: Article

References (48)

1. American Cancer Society Global Cancer Facts & Figures. 2nd edn, Atlanta, GA, USA, 2011.
2. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002; 2: 101-112.
3. Ross JS, Fletcher Ja, Bloom KJ, Linette GP, Stec J, Symmans WF et al. Targeted therapy in breast cancer: The HER-2/neu gene and protein. Mol Cell Proteomics 2004; 3: 379-398.
4. Verma S, Provencher L, Dent R. Emerging trends in the treatment of triple-negative breast cancer in Canada: A survey. Curr Oncol 2011; 18: 180-190.
5. Nagourney Ra, Link JS, Blitzer JB, Forsthoff C, Evans SS. Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients. J Clin Oncol 2000; 18: 2245-2249.
6. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nature reviews. Cancer 2007; 7: 573-584.
7. Shamseddine AI, Farhat FS. Platinum-based compounds for the treatment of metastatic breast cancer. Chemotherapy 2011; 57: 468-487.
8. Siddik ZH. Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22: 7265-7279.
9. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O et al. Molecular mechanisms of cisplatin resistance. Oncogene Nature Publishing Group 2011; 31: 1869-1883.
10. Jackson S, Bartek J. The DNA-damage response in human biology and disease. Nature 2009; 461: 1071-1078.
11. Basu A, Krishnamurthy S. Cellular responses to Cisplatin-induced DNA damage. JNucleic Acids 2010; 2010: 201367.
12. Sinclair CS, Adem C, Naderi A, Soderberg CL, Johnson M, Wu K et al. TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors. Cancer Res 2002; 62: 3587-3591.
13. Peres J, Davis E, Mowla S, Bennett DC, Li JA, Wansleben S et al. The Highly homologous T-Box transcription factors, TBX2 and TBX3, have distinct roles in the oncogenic process. Genes Cancer SAGE Publications 2010; 1: 272-282.
14. Jacobs J, Keblusek P, Robanus-Maandag E, Kristel P, Lingbeek M, Nederlof PM et al. Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breast cancers. Nature Genet 2000; 26: 291-299.
15. Lu J, Li X-P, Dong Q, Kung H-F, He M-L. TBX2 and TBX3: The special value for anticancer drug targets. Biochimica et biophysica acta Elsevier B.V. 2010; 1806: 268-274.
16. Redmond KL, Crawford NT, Farmer H, D'Costa ZC, O'Brien GJ, Buckley NE et al. T-box 2 represses NDRG1 through an EGR1-dependent mechanism to drive the proliferation of breast cancer cells. Oncogene Nature Publishing Group 2010; 29: 3252-3262.
17. Vance K, Carreira S, Brosch G, Goding C. Tbx2 is overexpressed and plays an important role in maintaining proliferation and suppression of senescence in melanomas. Cancer Res 2005; 65: 2260-2268.
18. Prince S, Carreira S, Vance KW, Abrahams A, Goding CR. Tbx2 directly represses the expression of the p21(WAF1) cyclin-dependent kinase inhibitor. Cancer Res 2004; 64: 1669-1674.
19. Abrahams A, Parker I, Prince S. The T-box transcription factor Tbx2: Its role in development and possible implication in cancer. IUBMB Life 2009; 62: 93-102.
20. Davis E, Teng H, Bilican B, Parker MI, Liu B, Carreira S et al. Ectopic Tbx2 expression results in polyploidy and cisplatin resistance. Oncogene 2008; 27: 976-984.
21. Ismail A, Bateman A. Expression of TBX2 promotes anchorage-independent growth and survival in the p53-negative SW13 adrenocortical carcinoma. Cancer Lett 2009; 278: 230-240.
22. Fan S, Smith ML, Rivet DJ, Duba D, Zhan Q, Kohn KW et al. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 1995; 55: 1649-1654.
23. Yde CW, Issinger O-G. Enhancing cisplatin sensitivity in MCF-7 human breast cancer cells by down-regulation of Bcl-2 and cyclin D1. Int J Oncol 2006; 29: 1397-1404.
24. Baldassarre G, Belletti B, Battista S, Nicoloso MS, Pentimalli F, Fedele M et al. HMGA1 protein expression sensitizes cells to cisplatin-induced cell death. Oncogene 2005; 24: 6809-6819.
25. Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB. p53 deficient cells rely on ATM and ATRmediated checkpoint signaling through the p38 MAPK/MK2pathway for survival after DNA damage. Cancer Cell 2007; 11: 175-189.
26. Levesque AA, Eastman A. p53-based cancer therapies: Is defective p53 the Achilles heel of the tumor? Carcinogenesis 2007; 28: 13-20.
27. Levesque AA, Fanous AA, Poh A, Eastman A. Defective p53 signaling in p53 wild-Type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest. Mol Cancer Ther 2008; 7: 252-262.
28. Bucher N, Britten CD. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer 2008; 98: 523-528.
29. Castedo M, Perfettini J, Roumier T, Andreau K, Medema R, Kroemer G. Cell death by mitotic catastrophe: A molecular definition. Oncogene 2004; 23: 2825-2837.
30. Willis N, Rhind N. Regulation of DNA replication by the S-phase DNA damage checkpoint. Cell Division 2009; 4: 13.
31. Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 2001; 15: 2177-2196.
32. Smith ML. Mdm2 sensitizes MCF7 breast cancer cells to cisplatin or carboplatin. Breast Cancer Res Treat 1999; 58: 99-105.
33. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM et al. WAF1, a Potential Mediator of p53 Tumor Suppression. Cell 1993; 75: 817-825.
34. Dhillon KK, Swisher EM, Taniguchi T. Secondary mutations of BRCA1/2 and drug resistance. Cancer Sci 2011; 102: 663-669.
35. Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008; 451: 1116-1120.
36. Manchado E, Guillamot M, Malumbres M. Killing cells by targeting mitosis. Cell Death Diff 2012; 19: 369-377.
37. Ricci MS, Zong W. Chemotherapeutic approaches for targeting cell death pathways. Oncologist 2006; 11: 342-357.
38. Liang X, Guo Y, Figg WD, Fojo AT, Mueller MD, Yu JJ. The role of wild-Type p53 in cisplatin-induced Chk2 phosphorylation and the inhibition of platinum resistance with a Chk2 inhibitor. Chem Res Practice 2010; 2011: 1-8.
39. Castedo M, Perfettini J, Roumier T, Yakushijin K, Horne D, Medema R et al. The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe. Oncogene 2004; 23: 4353-4361.
40. Yazlovitskaya EM, DeHaan RD, Persons DL. Prolonged wild-Type p53 protein accumulation and cisplatin resistance. Biochem Biophysic Res Commun 2001; 283: 732-737.
41. Bauer JA, Trask DK, Kumar B, Los G, Castro J, Lee JS-J et al. Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: Role of wild-Type p53 and Bcl-xL. Mol Cancer Ther 2005; 4: 1096-1104.
42. Bhana S, Hewer A, Phillips DH, Lloyd DR. P53-dependent global nucleotide excision repair of cisplatin-induced intrastrand cross links in human cells. Mutagenesis 2008; 23: 131-136.
43. Sangster-Guity N, Conrad BH, Papadopoulos N, Bunz F. ATR mediates cisplatin resistance in a p53 genotype-specific manner. Oncogene Nature Publishing Group 2011; 30: 2526-2533.
44. Abrahams A, Mowla S, Parker MI, Goding C, Prince S. UV-mediated regulation of the antisenescence factor Tbx2. J Biol Chem 2008; 283: 2223-2230.
45. Harrelson Z, Kelly RG, Goldin SN, Gibson-Brown JJ, Bollag RJ, Silver LM et al. Tbx2 is essential for patterning the atrioventricular canal and for morphogenesis of the outflow tract during heart development. Development 2004; 131: 5041-5052.
46. Jung Y-S, Qian Y, Chen X. Examination of the expanding pathways for the regulation of p21 expression and activity. Cellular Signal Elsevier B.V. 2010; 22: 1003-1012.
47. Jeong J-H, Kang S-S, Park K-K, Chang H-W, Magae J, Chang Y-C. p53-independent induction of G1 arrest and p21WAF1/CIP1 expression by ascofuranone, an isoprenoid antibiotic, through downregulation of c-Myc. Mol Cancer Ther 2010; 9: 2102-2113.
48. Huang L, Sowa Y, Sakai T, Pardee AB. Activation of the p21 WAF1 / CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene 2000; 19: 5712-5719.